Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Efficacy and Safety of Basal Insulin Glargine Combination with Exenatide bid vs Switching
Premix Human Insulin to Aspart30 in T2DM with Inadequate Glycaemic Control on Premixed Human
Insulin and Metformin: a Randomized, Open, Parallel trial.